I'm not familiar with that article.
What I can tell you is that the fast-tracking process, or the priority review process, is a way for us to put the products that have the potential to have a really significant impact on the lives of Canadians at the front of the queue. I want to make sure the committee is aware, however, that we go through the same review process, and we ensure that the data is there to support the claims for those products.
It's not surprising to us in one way to think that the products that have the potential to really change the lives of Canadians with severe life-threatening diseases would also carry some risk. The diseases themselves carry great risks. It is always the case that manufacturers continue developing their products even after licensing and approval. It's not unusual for us to have more than 100 interactions with companies during the life of their product on the market. Even with these therapies, we would expect that companies continue to develop information, provide that to us, and ensure that the appropriate risk and benefits are really provided to Canadians and to the prescribing health care professionals.